小剂量米托蒽醌的MEA方案治疗老年急性髓系白血病疗效观察  

Efficacy analysis of the low dose of mitoxantrone, etoposide, cytarabine in the treatment of aged acute myelogenous leukemia

作　　者：谭琳[1] 谢瑜[1] 曾云[1] 杨坚[1] 

机构地区：[1]昆明医学院第一附属医院血液科,云南昆明650032

出　　处：《中国实用医刊》2008年第13期27-28,共2页Chinese Journal of Practical Medicine

摘　　要：目的探讨应用小剂量米托蒽醌的MEA方案与常规剂量米托蒽醌MEA方案治疗老年急性髓系白血病的疗效。方法将42例老年AML患者分为两组，治疗组（21例）应用米托蒽醌5mg／d，静脉滴注，第1～3天；足叶乙甙100mg／d，口服，第1～5天；阿糖胞苷100～150mg／d，第1～7天，静脉滴注。对照组（21例）应用米托蒽醌10mg／d，第1～3天；足叶乙甙100mg／d，静脉滴注，第1～5天；阿糖胞苷150～200mg／d，第1～7天，静脉滴注。结果治疗组完全缓解（CR）率57．14％，总有效率80．95％，对照组CR率52．39％，总有效率76.19％。两组CR率差异无统计学意义（P〉0．05）。治疗组粒缺发生率、粒缺持续时间及发热持续时间均低于对照组，差异有统计学意义（P〈0．05）。结论小剂量米托蒽醌MEA方案治疗老年急性髓系白血病疗效确切，毒副作用少。Objective To evaluate the effifeacy of the low dose and conventijonal dose of mitoxantrone （MTZ, M） ,etoposide （Vp16,E） ,cytarabine （Ara- c, A） in the treatment of old acute myelogenous leukemia（AML）, Methods Forty -two eases with old AML were randomly divided into the low dose MEA group and conventional MEA group. The low dose MEA group （21 eases） were treated with the low dose MEA （M 5 mg/d）, iv. 1 -3 d,Vp16 100 mg/d. po. 1 -5 d;Ara - c 100 - 150 mg/d. iv. q12 h,1 -7 d）. Conventional MEA group （21 eases） were contrasted with conventional MEA （M 10 mg/d,iv,1 -3 d;Vp16 100 mg/d,iv,1 -5 d;Ara -c 150 -200 mg/d,iv,q12 h,1 -7 d）. Results Complete remission （Cr） rate was 57.14% ,the total effective rate was 80. 95% in the treatment group;Cr rate was 52. 39% ,total effect rate was 76, 19% in contrast group. Cr had no significant difference in the two groups （ P 〉 0.05 ）. It was lower in the low dose MEA group with the agranuloeytosis rate, agranuloagtos time and fever time than those in the control group （ P 〈 0.05 ）. Conclusion The low dose MEA is effective to old AML and the adverse effect is low.

关 键 词：急性髓系白血病 米托蒽醌 足叶乙甙 阿糖胞苷 

分 类 号：R733.7[医药卫生—肿瘤]